Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention
Renate M. Hoogeveen(Amsterdam University Medical Centers), Erik S.G. Stroes(Amsterdam UMC Location University of Amsterdam), Michiel J. Bom(Amsterdam UMC Location Vrije Universiteit Amsterdam), João Pereira(Amsterdam University Medical Centers), Wolfgang Köenig(Brigham and Women's Hospital), Paul Knaapen(Amsterdam University Medical Centers), Nick S. Nurmohamed(Amsterdam Neuroscience), Kay‐Tee Khaw(University of Cambridge), Andrea Baragetti(University of Milan), Evgeni Levin(Amsterdam University Medical Centers), S. Matthijs Boekholdt(The University of Texas Health Science Center at Houston), Alberico L. Catapano(University of Milan), Albert K. Groen(Amsterdam UMC Location University of Amsterdam), Nicholas J. Wareham(MRC Epidemiology Unit), V. Zampoleri(University of Milan)
Cited by 128
Related Papers
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
|Journal of the American College of Cardiology|2020|11k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
|European Heart Journal|2016|3.2k